Clinical use of intravenous iron: administration, efficacy, and safety.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Hematology. American Society of Hematology. Education Program

• Publication date

  2010-12-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/asheducation-2010.1.338PMID 21239816
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Intravenous iron dextran for severe refractory restless legs syndrome.

  2010cited by this paper
• The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study

  2010cited by this paper
• Chemo- and Radiotherapy Induce Common Apoptotic Mediators in Hodgkin's Lymphoma.

  2009cited by this paper
• Ferric carboxymaltose in patients with heart failure and iron deficiency.

  2009cited by this paper
• Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients.

  2009cited by this paper
• Anemia and inflammatory bowel diseases.

  2009cited by this paper
• Rapid (Sixty Minutes) Infusion of One Gram of Low Molecular Iron Dextran: Safety and Efficacy Profile.

  2009cited by this paper
• Intravenous iron in inflammatory bowel disease.

  2009cited by this paper
• BLOOD MANAGEMENT: Large‐dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial

  2009cited by this paper
• Tranexamic acid for reducing transfusion requirements after total knee arthroplasty: can efficacy and cost ratios be improved?

  2008cited by this paper
• Efficacy and safety of intravenous iron therapy as an alternative/adjunct to allogeneic blood transfusion

  2008cited by this paper
• High-molecular weight iron dextran: a wolf in sheep's clothing?

  2008cited by this paper
• The role of intravenous iron in anemia management and transfusion avoidance

  2008cited by this paper
• A Novel Intravenous Iron Formulation for Treatment of Anemia in Inflammatory Bowel Disease: The Ferric Carboxymaltose (FERINJECT®) Randomized Controlled Trial

  2008cited by this paper
• Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin.

  2008cited by this paper
• Establishing an anemia clinic for optimal erythropoietic-stimulating agent use in hematology-oncology patients.

  2008cited by this paper
• Safety of ferumoxytol in patients with anemia and CKD.

  2008cited by this paper
• Intravenous iron: From anathema to standard of care

  2008cited by this paper
• Darbepoetin-Alfa and I.V. Iron Administration after Autologous Hematopoietic Stem Cell Transplantation: A Prospective Randomized Multicenter Trial

  2008cited by this paper
• Second Annual Snowbird Conference on Clinical Management of Inflammatory Bowel Diseases and Intestinal Failure March 9–12, 2006

  2007cited by this paper
• Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy.

  2007cited by this paper
• Adverse events associated with intravenous iron infusion (low-molecular-weight iron dextran and iron sucrose): a systematic review

  2007cited by this paper
• Tolerability and efficacy of parenteral iron therapy in hemodialysis patients, a comparison of preparations

  2007cited by this paper
• Clinical update: intravenous iron for anaemia.

  2007cited by this paper
• Is There a Difference between the Allergic Potencies of the Iron Sucrose and Low Molecular Weight Iron Dextran?

  2007cited by this paper
• Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study.

  2007cited by this paper
• Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron.

  2006cited by this paper
• Update on adverse drug events associated with parenteral iron.

  2006cited by this paper
• Benchmarking iron dextran sensitivity: reactions requiring resuscitative medication in incident and prevalent patients.

  2005cited by this paper
• Iron and infection: the heart of the matter.

  2005cited by this paper
• A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD.

  2005cited by this paper
• Time-dependent associations between iron and mortality in hemodialysis patients.

  2005cited by this paper
• Administration of intravenous iron sucrose as a 2-minute push to CKD patients: a prospective evaluation of 2,297 injections.

  2005cited by this paper
• Iron, anaemia, and inflammatory bowel diseases

  2004cited by this paper
• On the relative safety of parenteral iron formulations.

  2004cited by this paper
• Non-transferrin-bound iron in the serum of hemodialysis patients who receive ferric saccharate: no correlation to peroxide generation.

  2004cited by this paper
• Evaluation of a service reconfiguration for managing intravenous iron supplementation in non-haemodialysis patients with chronic renal failure

  2004cited by this paper
• Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens.

  2004cited by this paper
• Structure, chemistry, and pharmacokinetics of intravenous iron agents.

  2004cited by this paper
• Administration of parenteral iron and mortality among hemodialysis patients.

  2004cited by this paper
• Intravenous Iron and the Risk of Infection in End‐Stage Renal Disease Patients

  2004cited by this paper
• Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease.

  2004cited by this paper
• Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial.

  2004cited by this paper
• Safety of Iron Sucrose in Hemodialysis Patients Intolerant to Other Parenteral Iron Products

  2004cited by this paper
• Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients.

  2003cited by this paper
• Chronic use of sodium ferric gluconate complex in hemodialysis patients: safety of higher-dose (> or =250 mg) administration.

  2003cited by this paper
• Total dose intravenous infusion of iron dextran for iron-deficiency anemia in children with inflammatory bowel disease.

  2002cited by this paper
• Intravenous iron administration does not significantly increase the risk of bacteremia in chronic hemodialysis patients.

  2002cited by this paper
• Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran.

  2002cited by this paper
• Safety and efficacy of sodium ferric gluconate complex in patients with chronic kidney disease.

  2002cited by this paper
• Suspected iron dextran-related adverse drug events in hemodialysis patients.

  2001cited by this paper
• Intravenous iron sucrose: establishing a safe dose.

  2001cited by this paper
• Adverse Events in Chronic Hemodialysis Patients Receiving Intravenous Iron Dextran – A Comparison of Two Products

  2000cited by this paper
• Intravenous iron dextran therapy in patients with iron deficiency and normal renal function who failed to respond to or did not tolerate oral iron supplementation.

  2000cited by this paper
• Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans.

  1999cited by this paper
• Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial.

  1998cited by this paper
• A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients.

  1998cited by this paper
• Erythropoietin for end-stage renal disease.

  1998cited by this paper
• Maintaining iron balance with total-dose infusion of intravenous iron dextran.

  1998cited by this paper
• Intravenous Iron and Erythropoietin for Anemia Associated with Crohn Disease

  1997cited by this paper
• The safety of intravenous iron dextran in hemodialysis patients.

  1996cited by this paper
• Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis.

  1996cited by this paper
• Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation.

  1995cited by this paper
• Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial.

  1987cited by this paper
• Intravenous iron dextran in clinical medicine.

  1980cited by this paper
• The adverse effect of iron repletion on the course of certain infections.

  1978cited by this paper
• Raised mean cell volume and meningoencephalitis associated with Mycoplasma pneumoniae infection.

  1977cited by this paper
• Sarcoma after intramuscular iron injection.

  1973cited by this paper
• Comparative therapeutic study of T.D.I. and I.M. injections of iron dextran complex in anaemia.

  1973cited by this paper
• TREATMENT OF 300 CASES OF IRON DEFICIENCY OF PREGNANCY BY TOTAL DOSE INFUSION OF IRON-DEXTRAN COMPLEX.

  1965cited by this paper
• TREATMENT OF 300 CASES OF IRON DEFICIENCY OF PREGNANCY BY TOTAL DOSE INFUSION OF IRON‐DEXTRAN COMPLEX

  1964cited by this paper
• Intramuscular iron therapy in iron-deficiency anaemia.

  1954cited by this paper
• Intravenous administration of iron.

  1947cited by this paper
• Rest versus activity in the treatment of a fracture.

  1947cited by this paper
• QUANTITATIVE ASPECTS OF IRON DEFICIENCY IN HYPOCHROMIC ANEMIA: (The Parenteral Administration of Iron).

  1932cited by this paper
• The Treatment of Chlorosis by Iron and some Other Drugs

  1893cited by this paper

• Ferric Derisomaltose Compared to Iron Sucrose in Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials

  2026cites this paper
• Iron Therapy in Pediatric Iron Deficiency and Iron-Deficiency Anemia: Efficacy, Safety, and Formulation-Specific Trade-Offs—A Narrative Review

  2026influential citation
• Evaluating ferric carboxymaltose administration in elderly patients: Clinical outcomes, comparative characteristics in different care settings and cost analysis. A five year study.

  2025cites this paper
• Best practice for the size analysis of nanomedicines - An iron sucrose case study.

  2025cites this paper
• Management of patients with iron deficiency anemia in the context of primary health care. Guidelines

  2025cites this paper
• Distinct roles of ferric carboxymaltose and ferric derisomaltose on phosphate homeostasis in iron deficiency anemia.

  2025cites this paper
• Eisen in der Therapie der Anämie bei Nierenkrankheit

  2025cites this paper
• Computational Prediction of Tissue Iron Dynamics in Iron Deficiency Anemia Following Intravenous Ferric Carboxymaltose Therapy

  2025cites this paper
• PHARMACOVIGILANCE INSIGHTS: A RARE COHORT STUDY ON HYPERSENSITIVITY REACTIONS TO INTRAVENOUS IRON SUCROSE IN POSTPARTUM ANEMIC WOMEN AT TERTIARY CARE HOSPITAL, TAMILNADU

  2025cites this paper
• Impact of Intravenous Ferric Carboxymaltose on Quality of Life in Patients with Iron Deficiency Anemia: A Prospective Observational Study

  2025cites this paper
• AIM HD-CKD study: assessment of the efficacy and safety of ferric carboxymaltose in iron deficiency anemia management in haemodialysis patients with chronic kidney disease

  2025cites this paper
• Safety, pharmacokinetics, and efficacy of albuvirtide administered by intravenous bolus every 4 weeks in combination with oral dolutegravir in virologically suppressed adults living with HIV: A 24-week study.

  2025cites this paper
• Oral and Intravenous Iron Therapy.

  2025cites this paper
• The experiences of ferric carboxymaltose desensitization and provocation

  2025cites this paper
• Iron-carbohydrate complexes treating iron anaemia: Understanding the nano-structure and interactions with proteins through orthogonal characterisation.

  2024cites this paper
• Comparison of Oral Versus Intravenous Iron Therapy in Improving Hemoglobin Status in Patients of Chronic Kidney Disease

  2024cites this paper
• Strengthening the editorial team's expertise on extracellular vesicles and inorganic drug carriers: JCR welcomes Prof. Pieter Vader and Prof. Yu Seok Youn as associate editors.

  2024cites this paper
• Dissimilar ferric derisomaltose formulations - In vitro comparisons between an originator and its intended similars.

  2024cites this paper
• The Effect of Ferric Carboxymaltose on Fibroblast Growth Factor 23 (FGF23) in Children with Iron Deficiency Anemia Due to Gastrointestinal Diseases

  2024cites this paper
• Harnessing Hyperthermia: Molecular, Cellular, and Immunological Insights for Enhanced Anticancer Therapies

  2024cites this paper
• Intravenous iron versus blood transfusion for postpartum anemia: a systematic review and meta-analysis

  2024cites this paper
• Intravenous iron and iron deficiency anemia in patients with gastrointestinal cancer: A systematic review

  2024cites this paper
• A Survey on the implementation of Patient Blood Management programs in Italy

  2024cites this paper
• Exploring progress in iron supplement formulation approaches for treating iron deficiency anemia through bibliometric and thematic analysis

  2024cites this paper
• Engineered Extracellular Vesicles Driven by Erythrocytes Ameliorate Bacterial Sepsis by Iron Recycling, Toxin Clearing and Inflammation Regulation

  2024cites this paper
• Visible-light driven photocatalytic degradation of organic dyes by carbonized palladium-impregnated graphene oxide quantum dots

  2024cites this paper
• Nano-scale characterization of iron-carbohydrate complexes by cryogenic scanning transmission electron microscopy: Building the bridge to biorelevant characterization

  2024cites this paper
• Diagnosis and management of anemia in pediatric inflammatory bowel diseases: Clinical practice guidelines on behalf of the SIGENP IBD Working group.

  2024cites this paper
• Infusion Reactions With Alternative Therapies During the National Shortage of Iron Dextran

  2024cites this paper
• Exploiting Pharma 4.0 Technologies in the Non-Biological Complex Drugs Manufacturing: Innovations and Implications

  2023cites this paper
• Factors Governing the Erythropoietic Response to Intravenous Iron Infusion in Patients with Chronic Kidney Disease: A Retrospective Cohort Study

  2023cites this paper
• A systematic literature review and meta-analysis of the incidence of serious or severe hypersensitivity reactions after administration of ferric derisomaltose or ferric carboxymaltose

  2023cites this paper
• Putting square pegs in round holes: why traditional pharmacokinetic principles cannot universally be applied to iron-carbohydrate complexes.

  2023cites this paper
• Interpreting Iron Homeostasis in Congenital and Acquired Disorders

  2023cites this paper
• Critical nanomaterial attributes of iron-carbohydrate nanoparticles: leveraging orthogonal methods to resolve the 3-dimensional structure.

  2023cites this paper
• Intravenous iron and iron deficiency anemia in gastrointestinal cancer patients: a systematic review

  2023cites this paper
• Patient Blood Management in Pregnancy

  2023cites this paper
• The fatigue after infusion or transfusion pilot trial and feasibility study: A three‐armed randomized pilot trial of intravenous iron and blood transfusion for the treatment of postpartum anemia

  2023cites this paper
• Neurosurgical Applications of Magnetic Hyperthermia Therapy.

  2023cites this paper
• Criticality of Surface Characteristics of Intravenous Iron–Carbohydrate Nanoparticle Complexes: Implications for Pharmacokinetics and Pharmacodynamics

  2022cites this paper
• Ներերակայի՞ն, թե՞ ներքին ընդունում. ո՞րն ընտրել: Երկաթպակասորդային սակավարյունության բուժման նորագույն մոտեցումները

  2022cites this paper
• Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle

  2022cites this paper
• The role of oral iron in the treatment of adults with iron deficiency

  2022cites this paper
• Patient Blood Management programs for post-partum hemorrhage.

  2022cites this paper
• Bloodless surgery in urologic oncology: A review of hematologic, anesthetic, and surgical considerations.

  2022cites this paper
• Hypersensitivity to Intravenous Iron Preparations

  2022cites this paper
• Efficacy of Oral Versus Injectable Iron in Patients With Chronic Kidney Disease: A Two-Year Cross-Sectional Study Conducted at a Rural Teaching Hospital

  2022cites this paper
• Anemia por deficiencia de hierro en niños: manejo transfusional

  2022cites this paper
• New Insights into Iron Deficiency Anemia in Children: A Practical Review

  2022cites this paper
• Theranostic nanoparticles with disease-specific administration strategies

  2022cites this paper
• Magnetic Nanoparticles in Medicine: Progress, Problems, and Advances

  2022cites this paper
• Exanthematous Drug Eruption to Intravenous Iron: A Case Report

  2022cites this paper
• Intravenous Iron-Carbohydrate Nanoparticles and Their Similars. What Do We Choose?

  2022cites this paper
• Treatment of Iron Deficiency Anemia in CKD and End-Stage Kidney Disease

  2021cites this paper
• Preoperative Single-Dose Intravenous Iron Formulation to Reduce Postsurgical Complications in Patients Undergoing Major Abdominal Surgery: A Randomized Control Trial Feasibility Study (PIRCAS Trial Pilot)

  2021cites this paper
• Use of intravenous iron and risk of anaphylaxis: A multinational observational post‐authorisation safety study in Europe

  2021cites this paper
• Iron deficiency anemia in IBD: an overlooked comorbidity

  2021cites this paper
• Role of Iron in the Molecular Pathogenesis of Diseases and Therapeutic Opportunities.

  2021cites this paper
• Iron Deficiency in Celiac Disease: Prevalence, Health Impact, and Clinical Management

  2021cites this paper
• Contributions to the study of the complement system in IgA nephropathy and dialysis

  2021cites this paper
• Newer formulations of intravenous iron: a review of their chemistry and key safety aspects – hypersensitivity, hypophosphatemia, and cardiovascular safety

  2021cites this paper
• Antepartum and postpartum anemia: a narrative review.

  2021cites this paper
• Anemia management: a historical perspective

  2021cites this paper
• Rationale and design of the intravenous iron for treatment of anemia before cardiac surgery (ITACS) trial.

  2021cites this paper
• [Hypophosphatemia following the administration of intravenous iron formulations: A case report and literature review].

  2021cites this paper
• Iron Therapy in Chronic Kidney Disease: Days of Future Past

  2021cites this paper
• Management of hypersensitivity reactions to non-dextran iron products - new insights into predisposing risk factors.

  2021cites this paper
• Perioperative anemia management

  2021cites this paper
• Authors’ Reply to Michael Auerbach’s Comment on: “Frequency and Associated Costs of Anaphylaxis- and Hypersensitivity-Related Adverse Events for Intravenous Iron Products in the USA: An Analysis Using the US Food and Drug Administration Adverse Event Reporting System”

  2021cites this paper
• Eisengruppe: Elemente der achten Nebengruppe

  2021cites this paper
• Iron Deficiency Anemia in Celiac Disease

  2021cites this paper
• Comment on: Frequency and Associated Costs of Anaphylaxis- and Hypersensitivity-Related Adverse Events for Intravenous Iron Products in the USA: An Analysis Using the US Food and Drug Administration Adverse Event Reporting System

  2021cites this paper
• Iron Replacement in Hemodialysis Patients– A Review

  2021cites this paper
• Cancer therapy with iron oxide nanoparticles: Agents of thermal and immune therapies.

  2020influential citation
• Appetite and ghrelin levels in iron deficiency anemia and the effect of parenteral iron therapy: A longitudinal study

  2020cites this paper
• TCRM_A_243462 245..259

  2020cites this paper
• Efficacy of iron supplementation in patients with inflammatory bowel disease treated with anti-tumor necrosis factor-alpha agents

  2020cites this paper
• Acute Effects of Iron Sucrose and Iron Carboxymaltose on Endothelial Function in Nondialysis Chronic Kidney Disease Patients

  2020cites this paper
• IRON AND IRON DEFICIENCY ANEMIA - A REVIEW

  2020cites this paper
• Portuguese Consensus on Diagnosis, Treatment, and Management of Anemia in Pediatric Inflammatory Bowel Disease

  2020cites this paper
• Hypophosphatemia Associated with Intravenous Iron Therapies for Iron Deficiency Anemia: A Systematic Literature Review

  2020cites this paper
• Factors Influencing Safety and Efficacy of Intravenous Iron-Carbohydrate Nanomedicines: From Production to Clinical Practice.

  2020influential citation
• In vitro and in situ experiments to evaluate the biodistribution and cellular toxicity of ultrasmall iron oxide nanoparticles potentially used as oral iron supplements

  2020cites this paper
• EFFECT OF INTRAVENOUS IRON THERAPY ON SERUM FERRITIN AND HAEMOGOBIN LEVELS IN CHILDREN REPORTING WITH IRON DEFECIENCY ANAEMIA

  2020cites this paper
• RESULTADOS DE LA IMPLANTACIÓN DE UN PROTOCOLO DE CORRECCIÓN DE ANEMIA PREOPERATORIA EN LA RECUPERACIÓN INTENSIFICADA DE CIRUGÍA COLORRECTAL ELECTIVA

  2020cites this paper
• A Brief Review for Clinicians of Iron Metabolism and the Safety, Efficacy, and Rationale for Use of Intravenous Iron Products

  2020cites this paper
• Iron Therapy in Inflammatory Bowel Disease

  2020cites this paper
• Frequency and Associated Costs of Anaphylaxis- and Hypersensitivity-Related Adverse Events for Intravenous Iron Products in the USA: An Analysis Using the US Food and Drug Administration Adverse Event Reporting System

  2020cites this paper
• FOR A FEW STEPS TO..., OR HOW TO AVOID FOR IRON DEFICIENCY AT PREGNANCY. LITERATURE REVIEW

  2020cites this paper
• ERKRANKUNGEN DES BLUTES UND DES GERINNUNGSSYSTEMS, SOLIDE TUMOREN UND PRINZIPIEN DER INTERNISTISCHEN ONKOLOGIE

  2020cites this paper
• Iron Deficiency Anemia

  2020cites this paper
• Systemically delivered antibody-labeled magnetic iron oxide nanoparticles are less toxic than plain nanoparticles when activated by alternating magnetic fields

  2020cites this paper
• Snapshots of Iron Speciation: Tracking the Fate of Iron Nanoparticle Drugs via a Liquid Chromatography-Inductively Coupled Plasma-Mass Spectrometric Approach.

  2019cites this paper
• The impact of pre‐operative intravenous iron on quality of life after colorectal cancer surgery: outcomes from the intravenous iron in colorectal cancer‐associated anaemia (IVICA) trial

  2019cites this paper
• Assessment of Iron Profile among Sudanese Patients with Chronic Renal Failure in Shendi Town

  2019cites this paper
• Effectiveness of a patient blood management protocol on reduction of allogeneic red blood cell transfusions in orthopedic surgery.

  2019cites this paper
• Efficacy and safety of intravenous iron sucrose treatment in children with iron deficiency anemia

  2019cites this paper
• Iron III isomaltose induced hypersensitivity reaction

  2019cites this paper
• Intravenöse Eisensubstitution bei chronischer Erkrankung – bei wem, wann und wie?

  2019cites this paper
• Administration of Intravenous Iron Formulations Induces Complement Activation in-vivo

  2019cites this paper